Presentation for Nuevolution’s Annual General Meeting and video material based on the Annual report 2016/17 now available

Stockholm, 12 October 2017 -- At the Annual General Meeting, to be held today at 15:00 CEST, Nuevolution’s CEO Alex Haahr Gouliaev will make a presentation reviewing the results of fiscal year 2016/17. This presentation is now available on the company’s home page (

As an additional service to our shareholders and investors, Nuevolution has uploaded video material based on the Annual report 2016/17, which was released on 18 September 2017.

The following video material can be found on the company’s homepage:

  1. Introduction
  2. Nuevolution in brief
  3. The Grand Plan
  4. Meet the Board of Directors
  5. A very productive year - The CEO reports
  6. The year as seen by the CFO
  7. Research progress – The CSO reports
  8. How we do business by the CBO
  9. Chemetics® drug discovery technology explained
  10. Autoimmune diseases explained

“2016/17 was a very productive year for Nuevolution both in terms of deal making, technology breakthroughs and pipeline progress,” said Alex Haahr Gouliaev, CEO, and continued, “We would like to use this opportunity to thank investors and shareholders for supporting us during the year in the market place, and we hope that you will find the video material helpful and informative.”

For more information, please contact:

Alex Haahr Gouliaev, CEO

Phone: +45 3913 0902


Henrik Damkjær Simonsen, CFO

Phone: +45 3913 0947


Information about Nuevolution AB (publ)

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment option. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.

This information was released for publication on Thursday 12 October at 14:00 (CEST).

Nuevolution AB (publ) is listed at Nasdaq First North in Stockholm, Sweden (ticker: NUE.ST). Redeye AB acts as Certified Advisor to Nuevolution AB (publ). More information about Nuevolution can be found on:


About Us

Nuevolution is a biotechnology company with a unique business model, where continuous revenue generation and risk mitigation represent primary objectives. This strategy is executed by a “multiple shots at goal” approach in combination with reduced research costs, where simultaneous development of multiple programs in parallel is made possible. Nuevolution is the inventor of Chemetics®. Chemetics® is a patent protected drug discovery research platform, which enables identification of small molecule (tablet based) drug candidates much more effectively and at lower cost than what is possible by other conventional methods. Nuevolution applies its research platform for the identification and development of its own pipeline of drug candidates for treatment of cancer and chronic inflammatory diseases Nuevolution applies a business model that is unique for a biotechnology company with a primary focus on revenue generation and risk minimization (i.e. lower cost development) by having a number of programs developed in parallel. Nuevolution is the inventor of Chemetics® , a patent protected drug discovery platform which enables efficient discovery of novel chemical small molecule leads for specific indications addressing disease targets within the company’s therapeutic focus areas


Documents & Links